Navigation Links
Patients Who Bring Health Information from the Internet Get More Time with Doctor
Date:7/10/2008

94% of physicians report that patients bring health information from the Internet to discuss during office visits. The majority of physicians who have patients discussing information in the office report they spend more time with these patients as a result.

New York, NY (PRWEB) July 10, 2008 -- An increasing number of "healthcare overachievers" are bringing health information from the Internet to the doctor's office to discuss during the office visit. In fact, virtually all physicians report at least some of their patients arrive armed with health information from the Internet, according to the latest physician market research study released by pharmaceutical market research company Manhattan Research. These patients are being rewarded for their efforts, as the majority of physicians report that they spend more time with the patient as a result of their bringing information in to the office visit.

"The Internet has empowered consumers to take an increasingly active role in their healthcare management and their relationship with the physician," says Meredith Abreu Ressi, VP of research at Manhattan Research. "The conversation with the physician used to be a one-way, didactic interaction. But as consumers are increasingly bearing the responsibility for their healthcare costs and decisions, this balance of power is shifting. The Internet is a key tool consumers use to educate themselves on treatment options, and some empowered consumers are discussing their findings with their physician."

The trends in the article are derived from

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
2. Number of Patients Treated with an Antibiotic for MRSA Within U.S. Acute Care Hospitals Increased 8 Percent from 2006 to 2007
3. New Aptivus(R) (tipranavir) Oral Solution Approved for Treatment-Experienced Pediatric and Adolescent HIV Patients
4. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
5. Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia
6. Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
7. Novel Investigational Regimen Combining Radiation Enhancing Agent With Ibritumomab Tiuxetan (Zevalin(R)) Produces High Rate of Complete Responses in Patients With Rituximab-Refractory Follicular Non-Hodgkins Lymphoma
8. Ipsogen Launches MapQuant Dx(TM) Genomic Grade Test to Identify Breast Cancer Patients who Benefit From Chemotherapy
9. First Taxane-Based Non-Anthracycline Containing Chemotherapy in Combination With Herceptin (TCH) for HER2 Positive Early Breast Cancer Patients Obtains Approval From the FDA
10. Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkins Lymphoma
11. American Urological Association (AUA) Clinical Guidelines Recognizes Cryotherapy as Treatment Option for Prostate Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Martek Signs Sole-Source Supply Agreement with Fonterra 2Martek Signs Sole-Source Supply Agreement with Fonterra 3La Jolla Pharmaceutical Company - Value Play or Overvalued: TapeBeat.Com Trader Alert 2La Jolla Pharmaceutical Company - Value Play or Overvalued: TapeBeat.Com Trader Alert 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 2MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 3MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 4